<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Puma Biotechnology Inc — News on 6ix</title>
<link>https://6ix.com/company/puma-biotechnology-inc</link>
<description>Latest news and press releases for Puma Biotechnology Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 20:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/puma-biotechnology-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a94678dffbe2df10cb54.webp</url>
<title>Puma Biotechnology Inc</title>
<link>https://6ix.com/company/puma-biotechnology-inc</link>
</image>
<item>
<title>Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-to-host-conference-call-to-discuss-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-to-host-conference-call-to-discuss-first-quarter-2026-financial-results</guid>
<pubDate>Thu, 23 Apr 2026 20:15:00 GMT</pubDate>
<description>LOS ANGELES, April 23, 2026--Puma Biotechnology will host a conference call on May 7 at 1:30 p.m. PT, following release of its first quarter 2026 financial results.</description>
</item>
<item>
<title>Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and</description>
</item>
<item>
<title>Puma Biotechnology to Present at TD Cowen’s 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-to-present-at-td-cowens-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-to-present-at-td-cowens-46th-annual-health-care-conference</guid>
<pubDate>Mon, 23 Feb 2026 21:15:00 GMT</pubDate>
<description>LOS ANGELES, February 23, 2026--Puma Biotechnology CEO & President Alan Auerbach will provide a corporate overview at the TD Cowen Health Care Conference on March 2 at 2:30 pm ET.</description>
</item>
<item>
<title>Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-host-conference-call-210700204</link>
<guid isPermaLink="true">https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-host-conference-call-210700204</guid>
<pubDate>Thu, 12 Feb 2026 21:07:00 GMT</pubDate>
<description>LOS ANGELES, February 12, 2026--Puma Biotechnology will issue its fourth quarter and full year 2025 results, followed be a conference call, after the close on Feb. 26, 2026.</description>
</item>
<item>
<title>Rigel Appoints Michael P. Miller to the Board of Directors</title>
<link>https://6ix.com/company/puma-biotechnology-inc/news/rigel-appoints-michael-p-miller-to-the-board-of-directors-1</link>
<guid isPermaLink="true">https://6ix.com/company/puma-biotechnology-inc/news/rigel-appoints-michael-p-miller-to-the-board-of-directors-1</guid>
<pubDate>Tue, 03 Feb 2026 13:05:00 GMT</pubDate>
<description>Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Michael P. Miller to its Board of Directors. Mr. Miller has more than four decades of experience in commercial and leadership roles in the biotechnology and pharmaceutical industries.</description>
</item>
<item>
<title>Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-reports-inducement-awards-221500664</link>
<guid isPermaLink="true">https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-reports-inducement-awards-221500664</guid>
<pubDate>Wed, 07 Jan 2026 22:15:00 GMT</pubDate>
<description>LOS ANGELES, January 07, 2026--Puma Biotechnology reported inducement awards granted to December 2025 new hires, in accordance with Nasdaq Listing Rule 5635(c)(4).</description>
</item>
<item>
<title>Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)</title>
<link>https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-added-nasdaq-biotechnology-211000597</link>
<guid isPermaLink="true">https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-added-nasdaq-biotechnology-211000597</guid>
<pubDate>Mon, 22 Dec 2025 21:10:00 GMT</pubDate>
<description>LOS ANGELES, December 22, 2025--Puma Biotechnology was added to the Nasdaq Biotechnology Index effective after the close of trading on Dec. 19, 2025.</description>
</item>
<item>
<title>Puma Biotechnology Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-reports-third-quarter-210500885</link>
<guid isPermaLink="true">https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-reports-third-quarter-210500885</guid>
<pubDate>Thu, 06 Nov 2025 21:05:00 GMT</pubDate>
<description>LOS ANGELES, November 06, 2025--On 11/6/26, Puma Biotechnology issued its financials for Q3-2025 and hosted a conference to discuss operating results.</description>
</item>
<item>
<title>Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results</title>
<link>https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-host-conference-call-201000179</link>
<guid isPermaLink="true">https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-host-conference-call-201000179</guid>
<pubDate>Thu, 23 Oct 2025 20:10:00 GMT</pubDate>
<description>LOS ANGELES, October 23, 2025--Puma Biotechnology will issue financials and host a conference call on Nov. 6, 2025 to discuss its results for the third quarter of 2025.</description>
</item>
<item>
<title>Puma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-present-h-c-200700451</link>
<guid isPermaLink="true">https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-present-h-c-200700451</guid>
<pubDate>Tue, 02 Sep 2025 20:07:00 GMT</pubDate>
<description>LOS ANGELES, September 02, 2025--On 9/8/25, Puma Biotechnology CEO and President Alan Auerbach will present a company overview at the H.C. Wainwright Global Investment Conference.</description>
</item>
<item>
<title>Puma Biotechnology Reports Second Quarter Financial Results</title>
<link>https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-reports-second-quarter-200500365</link>
<guid isPermaLink="true">https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-reports-second-quarter-200500365</guid>
<pubDate>Thu, 07 Aug 2025 20:05:00 GMT</pubDate>
<description>LOS ANGELES, August 07, 2025--On 8/7/2025, Puma Biotechnology issued 2Q-2025 earnings results and followed with a conference call to discuss quarterly and year-to-date results.</description>
</item>
<item>
<title>Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-host-conference-call-201500328</link>
<guid isPermaLink="true">https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-host-conference-call-201500328</guid>
<pubDate>Thu, 24 Jul 2025 20:15:00 GMT</pubDate>
<description>LOS ANGELES, July 24, 2025--On August 7, 2025, Puma Biotechnology will host a conference call/webcast to review its financial results for the second quarter of 2025.</description>
</item>
<item>
<title>Puma Biotechnology Reports First Quarter Financial Results</title>
<link>https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-reports-first-quarter-200500493</link>
<guid isPermaLink="true">https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-reports-first-quarter-200500493</guid>
<pubDate>Thu, 08 May 2025 20:05:00 GMT</pubDate>
<description>LOS ANGELES, May 08, 2025--Puma Biotechnology release its 1Q'25 earnings results on May 8 after markets closed and followed with a conference call to discuss operating results.</description>
</item>
<item>
<title>Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients</title>
<link>https://6ix.com/company/puma-biotechnology-inc/news/er-kim-announces-exclusive-distribution-agreement-with-puma-biotechnology-to-commercialize-nerlynxr-neratinib-for-breast-cancer-patients</link>
<guid isPermaLink="true">https://6ix.com/company/puma-biotechnology-inc/news/er-kim-announces-exclusive-distribution-agreement-with-puma-biotechnology-to-commercialize-nerlynxr-neratinib-for-breast-cancer-patients</guid>
<pubDate>Wed, 30 Apr 2025 10:00:00 GMT</pubDate>
<description>This collaboration will provide early-stage HER2-positive breast cancer patients with access to the targeted therapy that can reduce the risk of cancer recurrence and spreadATHENS, Greece and LOS ANGELES, April 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies in the EMEA region, today announced that it has signed an agreement with Puma Biotechnology, Inc. (NASDAQ: PBYI) to commercialize NERLYNX® (neratinib) in s</description>
</item>
<item>
<title>Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025</title>
<link>https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-presents-clinical-data-190300939</link>
<guid isPermaLink="true">https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-presents-clinical-data-190300939</guid>
<pubDate>Mon, 28 Apr 2025 19:03:00 GMT</pubDate>
<description>LOS ANGELES, April 28, 2025--Puma Biotechnology announced Phase I data of trastuzumab deruxtecan plus neratinib in solid tumors with HER2 alterations was presented at AACR 2025.</description>
</item>
<item>
<title>Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-host-conference-call-201100008</link>
<guid isPermaLink="true">https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-host-conference-call-201100008</guid>
<pubDate>Thu, 24 Apr 2025 20:11:00 GMT</pubDate>
<description>LOS ANGELES, April 24, 2025--Puma Biotechnology will issue its 1Q-2025 results after market close on May 8, 2025, and follow with a conference call at 1:30 pm PT/4:30 pm ET.</description>
</item>
<item>
<title>Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025</title>
<link>https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-present-clinical-data-130000014</link>
<guid isPermaLink="true">https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-present-clinical-data-130000014</guid>
<pubDate>Wed, 26 Mar 2025 13:00:00 GMT</pubDate>
<description>LOS ANGELES, March 26, 2025--Puma Biotechnology will present clinical data on its drug neratinib in a poster presentation on April 28 at the 2025 AACR Annual Meeting.</description>
</item>
<item>
<title>Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-present-barclays-annual-223000038</link>
<guid isPermaLink="true">https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-present-barclays-annual-223000038</guid>
<pubDate>Wed, 05 Mar 2025 22:30:00 GMT</pubDate>
<description>LOS ANGELES, March 05, 2025--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:00 p.m. ET on Tuesday, March 11, at Barclays 27th Annual Global Healthcare Conference. The conference will be held at the Loews Miami Beach.</description>
</item>
<item>
<title>Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results</title>
<link>https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-reports-fourth-quarter-210500806</link>
<guid isPermaLink="true">https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-reports-fourth-quarter-210500806</guid>
<pubDate>Thu, 27 Feb 2025 21:05:00 GMT</pubDate>
<description>LOS ANGELES, February 27, 2025--Puma Biotechnology will issue its 4Q and FY-2024 earnings results after the close on Feb. 27 and follow with a conference call to discuss results.</description>
</item>
<item>
<title>Puma Biotechnology to Present at TD Cowen’s 45th Annual Health Care Conference</title>
<link>https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-present-td-cowen-211500151</link>
<guid isPermaLink="true">https://6ix.com/company/puma-biotechnology-inc/news/puma-biotechnology-present-td-cowen-211500151</guid>
<pubDate>Wed, 26 Feb 2025 21:15:00 GMT</pubDate>
<description>LOS ANGELES, February 26, 2025--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 11:10 a.m. ET on Wednesday, March 5, at the TD Cowen 45th Annual Health Care Conference. The conference will be held March 3–5, 2025 at the Boston Marriott Copley Place in Boston.</description>
</item>
</channel>
</rss>